The market seems to share this rosy outlook, since Biogen has a short interest of only 2.1%. This represents the percentage ...

Quantinno Capital Management LP lowered its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 62.8% during the third ...

Shares of Biogen Inc. BIIB shed 3.41% to $150.03 Friday, on what proved to be an all-around mixed trading session for the ...

Integrated Wealth Concepts LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 61.3% during the third ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...

It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined ...

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly because Leqembi for ...

Shares of Biogen Inc. BIIB slumped 0.84% to $156.46 Monday, on what proved to be an all-around dismal trading session for the ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Biogen (BIIB) was downgraded to hold by Jefferies over an anticipated royalty cut for Ocrevus, lackluster pipeline, and expected modest sales of Leqembi. Read more here.